Skip to main content
logo
Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
204.86
-0.25 (-0.12%)
Sep 15, 2026, 4:00 PM EDT - Market closed

Revolution Medicines Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---11.5835.3829.39
Revenue Growth
----67.27%20.38%-31.62%
Cost of Revenue
1,296987.33592.23419.44253.07186.95
Gross Profit
-1,296-987.33-592.23-407.86-217.69-157.56
Selling, General & Admin
330.91195.0497.368.1240.5930.45
Operating Expenses
330.91195.0497.368.1240.5930.45
Operating Income
-1,627-1,182-689.52-475.99-258.28-188.01
Interest Expense
-59.34-24.23----0.01
Interest & Investment Income
98.4690.6986.8847.489.150.93
Other Non Operating Income (Expenses)
-180.16-15.41.8-0.19--
EBT Excluding Unusual Items
-1,768-1,131-600.85-428.69-249.13-187.09
Merger & Restructuring Charges
----11.2--
Pretax Income
-1,768-1,131-600.85-439.89-249.13-187.09
Income Tax Expense
---0.75-3.52-0.42-
Net Income
-1,768-1,131-600.09-436.37-248.71-187.09
Net Income to Common
-1,768-1,131-600.09-436.37-248.71-187.09
Net Income Growth
------
Shares Outstanding (Basic)
1981901681138173
Shares Outstanding (Diluted)
1981901681138173
Shares Change
10.45%13.35%48.24%40.34%10.74%32.68%
EPS (Basic)
-8.92-5.95-3.58-3.86-3.08-2.57
EPS (Diluted)
-8.92-5.95-3.58-3.86-3.08-2.57
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-1,232-913.73-567.74-358.3-235.22-153.71
Free Cash Flow Per Share
-6.22-4.81-3.38-3.17-2.92-2.11
Operating Margin
----4110.41%-730.01%-639.70%
Profit Margin
----3768.28%-702.95%-636.58%
Free Cash Flow Margin
----3094.14%-664.83%-522.99%
EBITDA
-1,618-1,175-683-470.98-254.34-184.96
D&A For EBITDA
9.067.756.535.013.943.05
EBIT
-1,627-1,182-689.52-475.99-258.28-188.01
Revenue as Reported
---11.5835.3829.39
SEC Filings: 10-K · 10-Q